Stock BRPAU BIG ROCK PARTNERS ACQUISITION CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Big Rock Partners Acquisition Corp. Stock Nasdaq

Equities

BRPAU

US0894822024

Financials

Sales 2024 * - Sales 2025 * - Capitalization 41.52M 56.73M
Net income 2024 * -21M -28.69M Net income 2025 * -21M -28.69M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.76 x
P/E ratio 2025 *
-1.82 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data

Chart Big Rock Partners Acquisition Corp.

Dynamic Chart

Latest news about Big Rock Partners Acquisition Corp.

NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression CI
Certain Warrants of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024. CI
Certain Option awards of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024. CI
Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024. CI
Transcript : NRx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data DJ
NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results CI
NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression CI
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches MT
Top Premarket Decliners MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital MT
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics CI
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine) CI
More news

Latest transcript on Big Rock Partners Acquisition Corp.

Logo Big Rock Partners Acquisition Corp.
NRx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024
More transcripts

Analyst Recommendations on Big Rock Partners Acquisition Corp.

Ascendiant Capital Starts NRX Pharmaceuticals at Buy With $4 Price Target MT
HC Wainwright Starts NRX Pharmaceuticals at Buy With $2 Price Target MT
More recommendations

Press releases Big Rock Partners Acquisition Corp.

NRx Pharmaceuticals, Inc. to Participate in the EF Hutton Annual Global Conference on May 15, 2024 AQ
NRx Pharmaceuticals : Notice of Acceleration - Form 8-K PU
NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression AQ
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock AQ
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement AQ
More press releases

News in other languages on Big Rock Partners Acquisition Corp.

Relief Therapeutics a creusé sa perte nette en 2022
Bourse Zurich: dans le rouge, le SMI finit sous les 10'700 points
Relief et NRX finalisent le règlement de leur litige sur l'aviptadil
Relief und NRx unterzeichnen endgültige Vergleichsvereinbarungen
Relief Therapeutics promeut son trésorier directeur général
More news

Company Profile

Big Rock Partners Acquisition Corp. is a blank check company. The Company is formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The Company is not limited to a particular industry or geographic region for purposes of consummating a business combination. The Company has not commenced any business operation and has not generated any revenue.
Sector
-
Calendar
2024-08-11 - Q2 2024 Earnings Release (Projected)
More about the company
  1. Stock Market
  2. Equities
  3. BRPA Stock
  4. BRPAU Stock